At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 16 Oct 2003 No development reported - Preclinical for Transplant rejection in USA (unspecified route)
- 17 Sep 2001 Preclinical development for Transplant rejection in USA (Unknown route)